Skip to main content

Baxter International Inc.

corporate_fare Company Profile

Baxter International Inc.

BAX·NYSE·Industrial Applications And Services·CIK 0000010456

Baxter International Inc., through its subsidiaries, provides a wide range of essential healthcare products. These include sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. These products are utilized in various healthcare settings such as hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and by patients at home under physician supervision. The company's global presence and the critical nature of its products and services are important for expanding access to healthcare in both emerging and developed countries. As of December 31, 2025, following the sale of its Kidney Care business, Baxter International Inc. manufactured products in over 20 countries and sold them in over 100 countries. The company was incorporated under Delaware law in 1931. Since January 2023, Baxter International Inc. has undertaken several strategic actions, including the sale of its Kidney Care business. On August 12, 2024, the company entered into an Equity Purchase Agreement with affiliates of Carlyle Group Inc. to sell its Kidney Care business, now known as Vantive Health LLC. The sale was completed on January 31, 2025, for an aggregate purchase price of $3.80 billion in cash, subject to certain adjustments. After these adjustments, the company received approximately $3.71 billion in pre-tax cash proceeds at closing, with net after-tax proceeds of approximately $3.3 billion, before certain post-closing adjustments.

Baxter International Inc. (NYSE:BAX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 25 items for BAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for BAX spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Baxter 10-Q Details $253M Debt Gain, $1.07B Cash Flow, New FDA Warning Letter
  • Baxter Swings to $294M Q3 Profit, Lifts 2026 Sales and EPS Guidance
  • Baxter Beats on Q3 Sales of $2.98B, Raises Full-Year 2026 Outlook
  • Baxter Posts $294M Third-Quarter Net Income
  • Baxter Names John Rogers as CFO, Filling Key Leadership Gap

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$11.24B
Net Income
-$957M
Diluted EPS
-$1.87
Op. Cash Flow
$845M
Free Cash Flow
$332M
Gross Profit
$3.38B
Operating Income
-$308M
Cash & Equivalents
$1.97B
Total Debt
$1M
Debt / Equity
0.00×
Net Margin
-8.5%
Shares Outstanding
513M sh
Source: 10-K · filed 2026-02-12 · accession 0001628280-26-007733

Short Interest & Short Volume

3.00 days to cover

FINRA reported short interest of 23,674,982 shares in BAX as of the October 30, 2026 settlement, a 0.4% decrease from the prior period — about 3.0 days to cover at its recent average daily volume. On November 20, 2026, 47.8% of BAX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)23,674,982 shares as of October 30, 2026
Change vs prior period▼ 0.4%
Days to cover3.00 at avg daily volume of 7,900,719
Daily short volume (FINRA facilities)47.8% of 1,169,214 shares on November 20, 2026
5-day average short volume55.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$25.43 +0.16% today
52-week range · as of 2026-10-29 $15.73 – $30
Market cap
$13.14B
Volume
4.3M (0.7× avg)
3-mo avg 6.5M
Live data · 2026-11-21 16:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BAX - Latest Insights

BAX
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $25.43 info
Change: +$2.49 (+11%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 8:06 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $25.43 info
Change: -$0.570 (-2%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.74
Real-time Price: $25.43 info
Change: -$1.31 (-5%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.50
Real-time Price: $25.43 info
Change: -$1.07 (-4%) info
Market Cap: $13.135B info
BAX
Aug 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.20
Real-time Price: $25.43 info
Change: -$0.770 (-3%) info
Market Cap: $13.135B info
BAX
Aug 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.88
Real-time Price: $25.43 info
Change: -$0.450 (-2%) info
Market Cap: $13.135B info
BAX
Aug 04, 2026, 5:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.05
Real-time Price: $25.43 info
Change: -$2.62 (-9%) info
Market Cap: $13.135B info
BAX
Jul 30, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.25
Real-time Price: $25.43 info
Change: -$0.820 (-3%) info
Market Cap: $13.135B info
BAX
Jul 30, 2026, 11:33 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $26.71
Real-time Price: $25.43 info
Change: -$1.28 (-5%) info
Market Cap: $13.135B info
BAX
Jul 30, 2026, 7:26 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $25.43 info
Change: -$3.07 (-11%) info
Market Cap: $13.135B info
BAX
Jul 30, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.69
Real-time Price: $25.43 info
Change: -$2.26 (-8%) info
Market Cap: $13.135B info
BAX
Jul 30, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.20
Real-time Price: $25.43 info
Change: +$0.230 (+0.91%) info
Market Cap: $13.135B info
BAX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.99
Real-time Price: $25.43 info
Change: +$7.44 (+41%) info
Market Cap: $13.135B info
BAX
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.01
Real-time Price: $25.43 info
Change: +$7.42 (+41%) info
Market Cap: $13.135B info
BAX
Apr 30, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.44
Real-time Price: $25.43 info
Change: +$7.99 (+46%) info
Market Cap: $13.135B info
BAX
Apr 30, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $17.75
Real-time Price: $25.43 info
Change: +$7.68 (+43%) info
Market Cap: $13.135B info
BAX
Apr 30, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $17.33
Real-time Price: $25.43 info
Change: +$8.10 (+47%) info
Market Cap: $13.135B info
BAX
Mar 24, 2026, 9:45 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $16.41
Real-time Price: $25.43 info
Change: +$9.02 (+55%) info
Market Cap: $13.135B info
BAX
Mar 23, 2026, 8:52 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $16.41
Real-time Price: $25.43 info
Change: +$9.02 (+55%) info
Market Cap: $13.135B info
BAX
Mar 23, 2026, 8:51 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $16.41
Real-time Price: $25.43 info
Change: +$9.02 (+55%) info
Market Cap: $13.135B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets